Vascular inflammation and atherosclerosis: The role of estrogen receptors

Current Medicinal Chemistry

Volumn 22, Issue 22, 2015, Pages 2651-2665

  Kassi, Eva ^a   Spilioti, Eliana ^a   Nasiri Ansari, Narjes ^a   Adamopoulos, Christos ^a   Moutsatsou, Paraskevi ^a   Papapanagiotou, Aggeliki ^a   Siasos, Gerasimos ^a   Tousoulis, Dimitris ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Endothelial cells; Estrogen receptor alpha; Estrogen receptor beta; GPR 30; Vascular inflammation; Vascular smooth muscle cells

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; ESTROGEN; ESTROGEN RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; ENDOTHELIUM CELL; HORMONE SUBSTITUTION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; FEMALE; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ATHEROSCLEROSIS; ENDOTHELIAL CELLS; ESTROGENS; FEMALE; HUMANS; INFLAMMATION; RECEPTORS, ESTROGEN;

EID: 84940879542     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150608093607     Document Type: Review

References (172)

1. Gaziano, T. A.; Bitton, A.; Anand, S.; Abrahams-Gessel, S.; Murphy, A. Growing epidemic of coronary heart disease in low- And middleincome countries. Curr. Probl. Cardiol., 2010, 35(2), 72-115.
2. Mendelsohn, M. E.; Karas, R. H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med., 1999, 340(23), 1801-1811.
3. Reckelhoff, J. F. Gender differences in the regulation of blood pressure. Hypertension, 2001, 37(5), 1199-208.
4. Kannel, W. B.; Wilson, P. W. Risk factors that attenuate the female coronary disease advantage. Arch. Intern. Med., 1995, 155(1), 57- 61.
5. Punnonen, R.; Jokela, H.; Aine, R.; Teisala, K.; Salomaki, A.; Uppa, H. Impaired ovarian function and risk factors for atherosclerosis in premenopausal women. Maturitas, 1997, 27(3), 231-238.
6. Stampfer, M. J.; Colditz, G. A.; Willett, W. C.; Manson, J. E.; Rosner, B.; Speizer, F. E.; Hennekens, C. H. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N. Engl. J. Med., 1991, 325(11), 756- 762.
7. Grady, D.; Rubin, S. M.; Petitti, D. B.; Fox, C. S.; Black, D.; Ettinger, B.; Ernster, V. L.; Cummings, S. R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med., 1992, 117(12), 1016-1037.
8. Grodstein, F.; Stampfer, M. J.; Manson, J. E.; Colditz, G. A.; Willett, W. C.; Rosner, B.; Speizer, F. E.; Hennekens, C. H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med., 1996, 335(7), 453-461.
9. Simoncini, T.; Genazzani, A. R. Direct vascular effects of estrogens and selective estrogen receptor modulators. Curr. Opin. Obstet. Gynecol., 2000, 12(3), 181-187.
10. Adams, M. R.; Kaplan, J. R.; Koritnik, D. R.; Clarkson, T. B. Pregnancy- Associated inhibition of coronary artery atherosclerosis in monkeys. Evidence of a relationship with endogenous estrogen. Arteriosclerosis, 1987, 7(4), 378-384.
11. Hodgin, J. B.; Krege, J. H.; Reddick, R. L.; Korach, K. S.; Smithies, O.; Maeda, N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J. Clin. Invest., 2001, 107(3), 333-340.
12. Sullivan, T. R. Jr.; Karas, R. H.; Aronovitz, M.; Faller, G. T.; Ziar, J. P.; Smith, J. J.; O'Donnell, T. F. Jr.; Mendelsohn, M. E. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J. Clin. Invest., 1995, 96(5), 2482-2488.
13. Hulley, S.; Grady, D.; Bush, T.; Furberg, C.; Herrington, D.; Riggs, B.; Vittinghoff, E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998, 280(7), 605-613.
14. Rossouw, J. E.; Anderson, G. L.; Prentice, R. L.; LaCroix, A. Z.; Kooperberg, C.; Stefanick, M. L.; Jackson, R. D.; Beresford, S. A.; Howard, B. V.; Johnson, K. C.; Kotchen, J. M.; Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288(3), 321-333.
15. Hansson, G. K. Inflammatory mechanisms in atherosclerosis. J. Thromb. Haemost., 2009, 7(Suppl 1), 328-331.
16. Libby, P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr., 2006, 83(2), 456S-460S.
17. Ross, R. Atherosclerosis is an inflammatory disease. Am. Heart J., 1999, 138(5 pt. 2), S419-S420.
18. Ross, R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature, 1993, 362(6423), 801-809.
19. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352(16), 1685-1695.
20. Arnal, J. F.; Douin-Echinard, V.; Brouchet, L.; Tremollieres, F.; Laurell, H.; Lenfant, F.; Gadeau, A. P.; Guery, J. C.; Gourdy, P. Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundam. Clin. Pharmacol., 2006, 20(6), 539-548.
21. van der Wal, A. C.; Das, P. K.; Tigges, A. J.; Becker, A. E. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am. J. Pathol., 1992, 141(6), 1427- 1433.
22. Crowther, M. A. Pathogenesis of atherosclerosis. Hematology Am. Soc. Hematol. Educ. Program., 2005, 2005, 436-441.
23. Shah, P. K.; Galis, Z. S. Matrix metalloproteinase hypothesis of plaque rupture: Players keep piling up but questions remain. Circulation, 2001, 104(16), 1878-1880.
24. Fuster, V.; Badimon, L.; Badimon, J. J.; Chesebro, J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med., 1992, 326(4), 242-250.
25. Nilsson, S.; Makela, S.; Treuter, E.; Tujague, M.; Thomsen, J.; Andersson, G.; Enmark, E.; Pettersson, K.; Warner, M.; Gustafsson, J. A. Mechanisms of estrogen action. Physiol. Rev., 2001, 81(4), 1535-1565.
26. Levin, E. R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab., 2009, 20(10), 477-482.
27. Bjornstrom, L.; Sjoberg, M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol., 2005, 19(4), 833-42.
28. Nabulsi, A. A.; Folsom, A. R.; White, A.; Patsch, W.; Heiss, G.; Wu, K. K.; Szklo, M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N. Engl. J. Med., 1993, 328(15), 1069-1075.
29. Collins, T.; Read, M. A.; Neish, A. S.; Whitley, M. Z.; Thanos, D.; Maniatis, T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J., 1995, 9(10), 899-909.
30. Koh, K. K.; Blum, A.; Hathaway, L.; Mincemoyer, R.; Csako, G.; Waclawiw, M. A.; Panza, J. A.; Cannon, R. O. 3rd, Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation, 1999, 100(18), 1851-1857.
31. Mori, M.; Tsukahara, F.; Yoshioka, T.; Irie, K.; Ohta, H. Suppression by 17beta-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci., 2004, 75(5), 599-609.
32. Simoncini, T.; Maffei, S.; Basta, G.; Barsacchi, G.; Genazzani, A. R.; Liao, J. K.; De Caterina, R. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ. Res., 2000, 87(1), 19- 25.
33. Van Baal, W. M.; Emeis, J. J.; Kenemans, P.; Kessel, H.; Peters- Muller, E. R.; Schalkwijk, C. G.; van der Mooren, M. J.; Stehouwer, C. D. Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules. Eur. J. Clin. Invest., 1999, 29(11), 913-921.
34. van Baal, W. M.; Kenemans, P.; van der Mooren, M. J.; Kessel, H.; Emeis, J. J.; Stehouwer, C. D. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb. Haemost., 1999, 81(6), 925-958.
35. Cossette, E.; Cloutier, I.; Tardif, K.; DonPierre, G.; Tanguay, J. F. Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. Mol. Cell. Biochem., 2013, 373(1-2), 137-147.
36. Arnal, J. F.; Batkai, S.; Elhage, R.; Darblade, B.; Rami, J.; Maret, A.; Bayard, F. Effect of estrogens on arterial physiology and mechanisms of their atherosclerosis-protective effect in animals. Therapie, 1999, 54(3), 339-346.
37. Matthys, K. E.; Bult, H. Nitric oxide function in atherosclerosis. Mediators Inflamm., 1997, 6(1), 3-21.
38. Arnal, J. F.; Clamens, S.; Pechet, C.; Negre-Salvayre, A.; Allera, C.; Girolami, J. P.; Salvayre, R.; Bayard, F. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc. Natl. Acad. Sci., USA 1996, 93(9), 4108-4113.
39. Caulin-Glaser, T.; Garcia-Cardena, G.; Sarrel, P.; Sessa, W. C.; Bender, J. R. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ. Res., 1997, 81(5), 885-892.
40. Hishikawa, K.; Nakaki, T.; Marumo, T.; Suzuki, H.; Kato, R.; Saruta, T. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett., 1995, 360(3), 291-293.
41. Russell, K. S.; Haynes, M. P.; Sinha, D.; Clerisme, E.; Bender, J. R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci. USA, 2000, 97(11), 5930-5935.
42. Mendelsohn, M. E.; Karas, R. H. Estrogen and the blood vessel wall. Curr. Opin. Cardiol., 1994, 9(5), 619-626.
43. Hisamoto, K.; Ohmichi, M.; Kurachi, H.; Hayakawa, J.; Kanda, Y.; Nishio, Y.; Adachi, K.; Tasaka, K.; Miyoshi, E.; Fujiwara, N.; Taniguchi, N.; Murata, Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem., 2001, 276(5), 3459-3467.
44. Haynes, M. P.; Sinha, D.; Russell, K. S.; Collinge, M.; Fulton, D.; Morales-Ruiz, M.; Sessa, W. C.; Bender, J. R. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ. Res., 2000, 87(8), 677-682.
45. Stefano, G. B.; Prevot, V.; Beauvillain, J. C.; Cadet, P.; Fimiani, C.; Welters, I.; Fricchione, G. L.; Breton, C.; Lassalle, P.; Salzet, M.; Bilfinger, T. V. Cell-surface estrogen receptors mediate calcium- dependent nitric oxide release in human endothelia. Circulation, 2000, 101(13), 1594-1597.
46. Chakrabarti, S.; Lekontseva, O.; Peters, A.; Davidge, S. T. 17beta- Estradiol induces protein S-nitrosylation in the endothelium. Cardiovasc. Res., 2010, 85(4), 796-805.
47. Bilsel, A. S.; Moini, H.; Tetik, E.; Aksungar, F.; Kaynak, B.; Ozer, A. 17Beta-estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovasc. Res., 2000, 46(3), 579-584.
48. Egan, K. M.; Lawson, J. A.; Fries, S.; Koller, B.; Rader, D. J.; Smyth, E. M.; Fitzgerald, G. A. COX-2-derived prostacyclin confers atheroprotection on female mice. Science, 2004, 306(5703), 1954-1957.
49. Luksha, L.; Poston, L.; Gustafsson, J. A.; Hultenby, K.; Kublickiene, K. The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J. Physiol., 2006, 577(pt. 3), 945-955.
50. Zhou, K.; Gao, Q.; Zheng, S.; Pan, S.; Li, P.; Suo, K.; Simoncini, T.; Wang, T.; Fu, X. 17beta-estradiol induces vasorelaxation by stimulating endothelial hydrogen sulfide release. Mol. Hum. Reprod., 2013, 19 (3), 169-76.
51. Alvarez, R. J.; Gips, S. J.; Moldovan, N.; Wilhide, C. C.; Milliken, E. E.; Hoang, A. T.; Hruban, R. H.; Silverman, H. S.; Dang, C. V.; Goldschmidt-Clermont, P. J. 17beta-estradiol inhibits apoptosis of endothelial cells. Biochem. Biophys. Res. Commun., 1997, 237(2), 372-381.
52. Morales, D. E.; McGowan, K. A.; Grant, D. S.; Maheshwari, S.; Bhartiya, D.; Cid, M. C.; Kleinman, H. K.; Schnaper, H. W. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation, 1995, 91(3), 755-763.
53. Geraldes, P.; Sirois, M. G.; Bernatchez, P. N.; Tanguay, J. F. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: Role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol., 2002, 22(10), 1585-1590.
54. Spyridopoulos, I.; Sullivan, A. B.; Kearney, M.; Isner, J. M.; Losordo, D. W. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation, 1997, 95(6), 1505-1514.
55. Seli, E.; Guzeloglu-Kayisli, O.; Cakmak, H.; Kayisli, U. A.; Selam, B.; Arici, A. Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating Fas and Fas ligand expression. J. Clin. Endocrinol. Metab., 2006, 91(12), 4995-5001.
56. Wang, L. L.; Zhao, J. L.; Lau, W. B.; Zhang, Y. Q.; Qiao, Z. D.; Wang, Y. J. Estradiol pretreatment attenuated nicotine-induced endothelial cell apoptosis via estradiol functional membrane receptor. Int. Immunopharmacol., 2011, 11(6), 675-682.
57. Ding, Q.; Hussain, Y.; Chorazyczewski, J.; Gros, R.; Feldman, R. D. GPER-independent effects of estrogen in rat aortic vascular endothelial cells. Mol. Cell. Endocrinol., 2014, [Epub ahead of print].
58. Caliceti, C.; Aquila, G.; Pannella, M.; Morelli, M. B.; Fortini, C.; Pinton, P.; Bonora, M.; Hrelia, S.; Pannuti, A.; Miele, L.; Rizzo, P.; Ferrari, R. 17beta-estradiol enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cells. PLoS One, 2013, 8(8), e71440.
59. Imanishi, T.; Hano, T.; Nishio, I. Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J. Hypertens., 2005, 23(9), 1699-1706.
60. Ruan, Y.; Wu, S.; Zhang, L.; Chen, G.; Lai, W. Retarding the senescence of human vascular endothelial cells induced by hydrogen peroxide: Effects of 17beta-estradiol (E2) mediated mitochondria protection. Biogerontology, 2014, 15(4), 367-375.
61. Evans, M. J.; Harris, H. A.; Miller, C. P.; Karathanasis, S. K.; Adelman, S. J. Estrogen receptors alpha and beta have similar activities in multiple endothelial cell pathways. Endocrinology, 2002, 143(10), 3785-3795.
62. Toth, B.; Scholz, C.; Saadat, G.; Geller, A.; Schulze, S.; Mylonas, I.; Friese, K.; Jeschke, U. Estrogen receptor modulators and estrogen receptor beta immunolabelling in human umbilical vein endothelial cells. Acta Histochem., 2009, 111(6), 508-519.
63. Jensen, I.; Rinaldo, C. H.; Berge, N.L.; Seternes, O. M.; Moens, U. Human umbilical vein endothelial cells lack expression of the estrogen receptor. Endothelium, 1998, 6(1), 9-21.
64. Chen, Z.; Yuhanna, I. S.; Galcheva-Gargova, Z.; Karas, R. H.; Mendelsohn, M. E.; Shaul, P. W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest., 1999, 103(3), 401-406.
65. Kim, H. P.; Lee, J. Y.; Jeong, J. K.; Bae, S. W.; Lee, H. K.; Jo, I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem. Biophys. Res. Commun., 1999, 263(1), 257-262.
66. Simoncini, T.; Rabkin, E.; Liao, J. K. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3- kinase in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2003, 23(2), 198-203.
67. Figtree, G. A.; McDonald, D.; Watkins, H.; Channon, K. M. Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: Relationship to acute activation of nitric oxide synthase. Circulation, 2003, 107(1), 120-126.
68. Sobrino, A.; Oviedo, P. J.; Novella, S.; Laguna-Fernandez, A.; Bueno, C.; Garcia-Perez, M. A.; Tarin, J. J.; Cano, A.; Hermenegildo, C. Estradiol selectively stimulates endothelial prostacyclin production through estrogen receptor-{alpha}. J. Mol. Endocrinol., 2010, 44(4), 237-246.
69. Billon-Gales, A.; Fontaine, C.; Douin-Echinard, V.; Delpy, L.; Berges, H.; Calippe, B.; Lenfant, F.; Laurell, H.; Guery, J. C.; Gourdy, P.; Arnal, J. F. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation, 2009, 120(25), 2567-2576.
70. Chambliss, K. L.; Yuhanna, I. S.; Anderson, R. G.; Mendelsohn, M. E.; Shaul, P. W. ERbeta has nongenomic action in caveolae. Mol. Endocrinol., 2002, 16(5), 938-946.
71. Christian, R. C.; Liu, P. Y.; Harrington, S.; Ruan, M.; Miller, V. M.; Fitzpatrick, L. A. Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- And postmenopausal women. J. Clin. Endocrinol. Metab., 2006, 91(7), 2713-2720.
72. Ihionkhan, C. E.; Chambliss, K. L.; Gibson, L. L.; Hahner, L. D.; Mendelsohn, M. E.; Shaul, P. W. Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ. Res., 2002, 91(9), 814-820.
73. Holm, A.; Andersson, K. E.; Nordstrom, I.; Hellstrand, P.; Nilsson, B. O. Down-regulation of endothelial cell estrogen receptor expression expression by the inflammation promoter LPS. Mol. Cell. Endocrinol., 2010, 319(1-2), 8-13.
74. Rivard, A.; Andres, V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol. Histopathol., 2000, 15(2), 557-571.
75. Cheng, B.; Song, J.; Zou, Y.; Wang, Q.; Lei, Y.; Zhu, C.; Hu, C. Responses of vascular smooth muscle cells to estrogen are dependent on balance between ERK and p38 MAPK pathway activities. Int. J. Cardiol., 2009, 134(3), 356-65.
76. Dubey, R. K.; Jackson, E. K.; Gillespie, D. G.; Zacharia, L. C.; Imthurn, B.; Keller, P. J. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogenactivated protein kinase activity. Arterioscler. Thromb. Vasc. Biol., 2000, 20(4), 964-972.
77. Mori-Abe, A.; Tsutsumi, S.; Takahashi, K.; Toya, M.; Yoshida, M.; Du, B.; Kawagoe, J.; Nakahara, K.; Takahashi, T.; Ohmichi, M.; Kurachi, H. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J. Endocrinol., 2003, 178(3), 417-426.
78. Dubey, R. K.; Gillespie, D. G.; Mi, Z.; Rosselli, M.; Keller, P. J.; Jackson, E. K. Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-adenosine pathway. Hypertension, 2000, 35(1 pt. 2), 262-266.
79. Shen, S.; Szameitat, A. J.; Sterr, A. Detection of infarct lesions from single MRI modality using inconsistency between voxel intensity and spatial location-a 3-D automatic approach. IEEE Trans. Inf. Technol. Biomed., 2008, 12(4), 532-540.
80. Albinsson, S.; Sessa, W. C. Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury? Physiol. Genomics, 2011, 43(10), 529-533.
81. Robinson, H. C.; Baker, A. H. How do microRNAs affect vascular smooth muscle cell biology? Curr. Opin. Lipidol., 2012, 23(5), 405-411.
82. Zhao, J.; Imbrie, G. A.; Baur, W. E.; Iyer, L. K.; Aronovitz, M. J.; Kershaw, T. B.; Haselmann, G. M.; Lu, Q.; Karas, R. H. Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2013, 33(2), 257-265.
83. Sivritas, D.; Becher, M. U.; Ebrahimian, T.; Arfa, O.; Rapp, S.; Bohner, A.; Mueller, C. F.; Umemura, T.; Wassmann, S.; Nickenig, G.; Wassmann, K. Antiproliferative effect of estrogen in vascular smooth muscle cells is mediated by Kruppel-like factor-4 and manganese superoxide dismutase. Basic Res. Cardiol., 2011, 106(4), 563-575.
84. Prasongsukarn, K.; Chaisri, U.; Chartburus, P.; Wetchabut, K.; Benjathummarak, S.; Khachansaksumet, V.; Maneerat, Y. Phenotypic alterations in human saphenous vein culture induced by tumor necrosis factor-alpha and lipoproteins: A preliminary development of an initial atherosclerotic plaque model. Lipids Health Dis., 2013, 12, 132.
85. Xing, D.; Feng, W.; Miller, A. P.; Weathington, N. M.; Chen, Y. F.; Novak, L.; Blalock, J. E.; Oparil, S. Estrogen modulates TNFalpha- induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(6), H2607-H2612.
86. Xing, D.; Oparil, S.; Yu, H.; Gong, K.; Feng, W.; Black, J.; Chen, Y. F.; Nozell, S. Estrogen modulates NFkappaB signaling by enhancing IkappaBalpha levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-beta. PLoS One, 2012, 7(6), e36890.
87. Jiang, P.; Xu, J.; Zheng, S.; Huang, J.; Xiang, Q.; Fu, X.; Wang, T. 17beta-estradiol down-regulates lipopolysaccharide-induced MCP- 1 production and cell migration in vascular smooth muscle cells. J. Mol. Endocrinol., 2010, 4(2), 87-97.
88. Toniolo, A.; Warden, E. A.; Nassi, A.; Cignarella, A.; Bolego, C. Regulation of SIRT1 in vascular smooth muscle cells from streptozotocin- diabetic rats. PLoS One, 2013, 8(5), e65666.
89. Zhang, H. N.; Li, L.; Gao, P.; Chen, H. Z.; Zhang, R.; Wei, Y. S.; Liu, D. P.; Liang, C. C. Involvement of the p65/RelA subunit of NF-kappaB in TNF-alpha-induced SIRT1 expression in vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2010, 397(3), 569-575.
90. Zhu, Y.; Bian, Z.; Lu, P.; Karas, R. H.; Bao, L.; Cox, D.; Hodgin, J.; Shaul, P. W.; Thoren, P.; Smithies, O.; Gustafsson, J. A.; Mendelsohn, M. E. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science, 2002, 295(5554), 505-508.
91. Hong, H. J.; Liu, J. C.; Chan, P.; Juan, S. H.; Loh, S. H.; Lin, J. G.; Cheng, T. H. 17beta-estradiol downregulates angiotensin-IIinduced endothelin-1 gene expression in rat aortic smooth muscle cells. J. Biomed. Sci., 2004, 11(1), 27-36.
92. Hodges, Y. K.; Tung, L.; Yan, X. D.; Graham, J. D.; Horwitz, K. B.; Horwitz, L. D. Estrogen receptors alpha and beta: Prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation, 2000, 101(15), 1792-1798.
93. Register, T. C.; Adams, M. R. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J. Steroid Biochem. Mol. Biol., 1998, 64(3-4), 187-191.
94. Tsutsumi, S.; Zhang, X.; Takata, K.; Takahashi, K.; Karas, R. H.; Kurachi, H.; Mendelsohn, M. E. Differential regulation of the inducible nitric oxide synthase gene by estrogen receptors 1 and 2. J. Endocrinol., 2008, 199(2), 267-273.
95. Han, G.; Yu, X.; Lu, L.; Li, S.; Ma, H.; Zhu, S.; Cui, X.; White, R. E. Estrogen receptor alpha mediates acute potassium channel stimulation in human coronary artery smooth muscle cells. J. Pharmacol. Exp. Ther., 2006, 316(3), 1025-1030.
96. Wang, S.; Zhu, X.; Cong, B.; You, X.; Wang, Y.; Wang, W.; Ni, X. Estrogenic action on arterial smooth muscle: Permissive for maintenance of CRHR2 expression. Endocrinology, 2012, 153(4), 1915- 1924.
97. Nakamura, Y.; Suzuki, T.; Miki, Y.; Tazawa, C.; Senzaki, K.; Moriya, T.; Saito, H.; Ishibashi, T.; Takahashi, S.; Yamada, S.; Sasano, H. Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol. Cell. Endocrinol., 2004, 219(1-2), 17-26.
98. Montague, C. R.; Hunter, M. G.; Gavrilin, M. A.; Phillips, G. S.; Goldschmidt-Clermont, P. J.; Marsh, C. B. Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation. Circ. Res., 2006, 99(5), 477-484.
99. Pare, G.; Krust, A.; Karas, R. H.; Dupont, S.; Aronovitz, M.; Chambon, P.; Mendelsohn, M. E. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ. Res., 2002, 90(10), 1087-1092.
100. Takahashi, K.; Ohmichi, M.; Yoshida, M.; Hisamoto, K.; Mabuchi, S.; Arimoto-Ishida, E.; Mori, A.; Tsutsumi, S.; Tasaka, K.; Murata, Y.; Kurachi, H. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J. Endocrinol., 2003, 178(2), 319- 329.
101. Watanabe, T.; Akishita, M.; Nakaoka, T.; Kozaki, K.; Miyahara, Y.; He, H.; Ohike, Y.; Ogita, T.; Inoue, S.; Muramatsu, M.; Yamashita, N.; Ouchi, Y. Estrogen receptor beta mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation. Cardiovasc. Res., 2003, 5(3), 734-744.
102. Karas, R. H.; Hodgin, J. B.; Kwoun, M.; Krege, J. H.; Aronovitz, M.; Mackey, W.; Gustafsson, J. A.; Korach, K. S.; Smithies, O.; Mendelsohn, M. E. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc. Natl. Acad. Sci., USA, 1999, 96(26), 15133-15136.
103. Iafrati, M. D.; Karas, R. H.; Aronovitz, M.; Kim, S.; Sullivan, T. R. Jr.; Lubahn, D. B.; O'Donnell, T. F. Jr.; Korach, K. S.; Mendelsohn, M. E. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat. Med., 1997, 3(5), 545-548.
104. Ueda, K.; Lu, Q.; Baur, W.; Aronovitz, M. J.; Karas, R. H. Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation. Arterioscler. Thromb. Vasc. Biol., 2013, 33(8), 1837-1843.
105. Frostegard, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med., 2013, 11, 117.
106. Straub, R. H. The complex role of estrogens in inflammation. Endocr. Rev., 2007, 28(5), 521-574.
107. Elhage, R.; Gourdy, P.; Jawien, J.; Brouchet, L.; Castano, C.; Fievet, C.; Hansson, G. K.; Arnal, J. F.; Bayard, F. The atheroprotective effect of 17beta-estradiol depends on complex interactions in adaptive immunity. Am. J. Pathol., 2005, 167(1), 267-274.
108. Robertson, A. K.; Hansson, G. K. T cells in atherogenesis: for better or for worse? Arterioscler. Thromb. Vasc. Biol., 2006, 26(11), 2421-2432.
109. Stemme, S.; Faber, B.; Holm, J.; Wiklund, O.; Witztum, J. L.; Hansson, G. K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA, 1995, 92(9), 3893-3897.
110. Young, J. L.; Libby, P.; Schonbeck, U. Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost., 2002, 88(4), 554-567.
111. Faas, M. M.; Bakker, W. W.; Valkhof, N.; Schuiling, G. A. Effect of estradiol and progesterone on the low-dose endotoxin-induced glomerular inflammatory response of the female rat. Am. J. Reprod. Immunol., 1999, 41(3), 224-231.
112. Kamada, M.; Irahara, M.; Maegawa, M.; Yasui, T.; Yamano, S.; Yamada, M.; Tezuka, M.; Kasai, Y.; Deguchi, K.; Ohmoto, Y.; Aono, T. B cell subsets in postmenopausal women and the effect of hormone replacement therapy. Maturitas, 2001, 37(3), 173-179.
113. Kamada, M.; Irahara, M.; Maegawa, M.; Ohmoto, Y.; Murata, K.; Yasui, T.; Yamano, S.; Aono, T. Transient increase in the levels of T-helper 1 cytokines in postmenopausal women and the effects of hormone replacement therapy. Gynecol. Obstet. Invest., 2001, 52(2), 82-88.
114. Gourdy, P.; Araujo, L. M.; Zhu, R.; Garmy-Susini, B.; Diem, S.; Laurell, H.; Leite-de-Moraes, M.; Dy, M.; Arnal, J. F.; Bayard, F.; Herbelin, A. Relevance of sexual dimorphism to regulatory T cells: Estradiol promotes IFN-gamma production by invariant natural killer T cells. Blood, 2005, 105(6), 2415-2420.
115. Ghisletti, S.; Meda, C.; Maggi, A.; Vegeto, E. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol. Cell. Biol., 2005, 25(8), 2957-2968.
116. Calippe, B.; Douin-Echinard, V.; Laffargue, M.; Laurell, H.; Rana- Poussine, V.; Pipy, B.; Guery, J. C.; Bayard, F.; Arnal, J. F.; Gourdy, P. Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. J. Immunol., 2008, 180(12), 7980-7988.
117. Greaves, D. R.; Gordon, S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J. Lipid Res., 2009, 50, S282-S286.
118. Hansson, G. K.; Libby, P. The immune response in atherosclerosis: A double-edged sword. Nat. Rev. Immunol., 2006, 6(7), 508-519.
119. Edfeldt, K.; Swedenborg, J.; Hansson, G. K.; Yan, Z. Q. Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. Circulation, 2002, 105(10), 1158-1161.
120. Doherty, T. M.; Shah, P. K.; Arditi, M. Lipopolysaccharide, tolllike receptors, and the immune contribution to atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2005, 25(5), e38; author reply e38- e39.
121. Hsieh, Y. C.; Frink, M.; Thobe, B. M.; Hsu, J. T.; Choudhry, M. A.; Schwacha, M. G.; Bland, K. I.; Chaudry, I. H. 17Beta-estradiol downregulates Kupffer cell TLR4-dependent p38 MAPK pathway and normalizes inflammatory cytokine production following trauma-hemorrhage. Mol. Immunol., 2007, 44(9), 2165-2172.
122. Suzuki, T.; Yu, H. P.; Hsieh, Y. C.; Choudhry, M. A.; Bland, K. I.; Chaudry, I. H. Estrogen-mediated activation of non-genomic pathway improves macrophages cytokine production following traumahemorrhage. J. Cell. Physiol., 2008, 214(3), 662-672.
123. Han, G.; White, R. E. G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease. World J. Cardiol., 2014, 6(6), 367-375.
124. Prossnitz, E. R.; Barton, M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol., 2011, 7(12), 715-726.
125. Chakrabarti, S.; Davidge, S. T. G-protein coupled receptor 30 (GPR30): A novel regulator of endothelial inflammation. PLoS One, 2012, 7(12), e52357.
126. Lindsey, S. H.; Carver, K. A.; Prossnitz, E. R.; Chappell, M. C. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2. Lewis female rat. J. Cardiovasc. Pharmacol., 2011, 57(5), 598-603.
127. Sanchez, A. M.; Flamini, M. I.; Zullino, S.; Gopal, S.; Genazzani, A. R.; Simoncini, T. Estrogen receptor-{alpha} promotes endothelial cell motility through focal adhesion kinase. Mol. Hum. Reprod., 2011, 17(4), 219-226.
128. Ding, Q.; Gros, R.; Limbird, L. E.; Chorazyczewski, J.; Feldman, R. D. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am. J. Physiol. Cell. Physiol., 2009, 297(5), C1178-C1187.
129. Yu, X.; Ma, H.; Barman, S. A.; Liu, A. T.; Sellers, M.; Stallone, J. N.; Prossnitz, E. R.; White, R. E.; Han, G. Activation of G proteincoupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle. Am. J. Physiol. Endocrinol. Metab., 2011, 301(5), E882-E228.
130. Lindsey, S. H.; da Silva, A. S.; Silva, M. S.; Chappell, M. C. Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation. Am. J. Physiol. Endocrinol. Metab., 2013, 305(1), E113-E118.
131. Haas, E.; Bhattacharya, I.; Brailoiu, E.; Damjanovic, M.; Brailoiu, G. C.; Gao, X.; Mueller-Guerre, L.; Marjon, N. A.; Gut, A.; Minotti, R.; Meyer, M. R.; Amann, K.; Ammann, E.; Perez- Dominguez, A.; Genoni, M.; Clegg, D. J.; Dun, N. J.; Resta, T. C.; Prossnitz, E. R.; Barton, M. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ. Res., 2009, 104(3), 288-291.
132. Meyer, M. R.; Amann, K.; Field, A. S.; Hu, C.; Hathaway, H. J.; Kanagy, N. L.; Walker, M. K.; Barton, M.; Prossnitz, E. R. Deletion of G protein-coupled estrogen receptor increases endothelial vasoconstriction. Hypertension, 2012, 59(2), 507-512.
133. Broughton, B. R.; Miller, A. A.; Sobey, C. G. Endotheliumdependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am. J. Physiol. Heart Circ. Physiol., 2010, 298(3), H1055-H1061.
134. Meyer, M. R.; Baretella, O.; Prossnitz, E. R.; Barton, M. Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182, 780. Pharmacology, 2010, 86(1), 58-64.
135. Li, Z. L.; Liu, J. C.; Liu, S. B.; Li, X. Q.; Yi, D. H.; Zhao, M. G. Improvement of vascular function by acute and chronic treatment with the GPR30 agonist G1 in experimental diabetes mellitus. PLoS One, 2012, 7(6), e38787.
136. Rowlands, D. J.; Chapple, S.; Siow, R. C.; Mann, G. E. Equolstimulated mitochondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: Roles for F-actin and GPR30. Hypertension, 2011, 57(4), 833-840.
137. Lindsey, S. H.; Liu, L.; Chappell, M. C. Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling. Steroids, 2014, 81, 99-102.
138. Holm, A.; Hellstrand, P.; Olde, B.; Svensson, D.; Leeb-Lundberg, L. M.; Nilsson, B. O. The G protein-coupled estrogen receptor 1 (GPER1/GPR30) agonist G-1 regulates vascular smooth muscle cell Ca(2)(+) handling. J. Vasc. Res., 2013, 50(5), 421-429.
139. Meyer, M. R.; Field, A. S.; Kanagy, N. L.; Barton, M.; Prossnitz, E. R. GPER regulates endothelin-dependent vascular tone and intracellular calcium. Life Sci., 2012, 91(13-14), 623-627.
140. Li, F.; Yu, X.; Szynkarski, C. K.; Meng, C.; Zhou, B.; Barhoumi, R.; White, R. E.; Heaps, C. L.; Stallone, J. N.; Han, G. Activation of GPER induces differentiation and inhibition of coronary artery smooth muscle cell proliferation. PLoS One, 2013, 8(6), e64771.
141. Mercier, I.; Mader, S.; Calderone, A. Tamoxifen and ICI 182, 780 negatively influenced cardiac cell growth via an estrogen receptorindependent mechanism. Cardiovasc. Res., 2003, 59(4), 883-892.
142. Holm, A.; Baldetorp, B.; Olde, B.; Leeb-Lundberg, L. M.; Nilsson, B. O. The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle. J. Vasc. Res., 2011, 48(4), 327- 335.
143. Bowling, M. R.; Xing, D.; Kapadia, A.; Chen, Y. F.; Szalai, A. J.; Oparil, S.; Hage, F. G. Estrogen effects on vascular inflammation are age dependent: Role of estrogen receptors. Arterioscler. Thromb. Vasc. Biol., 2014, 34(7), 1477-1485.
144. Zhou, Q.; Liao, J. K. Rho kinase: An important mediator of atherosclerosis and vascular disease. Curr. Pharm. Des., 2009, 15(27), 3108-3115.
145. Kurt, A. H.; Tiftik, R. N.; Un, I.; Ulker, S.; Buyukafsar, K. G protein- coupled estrogen receptor1 (GPER1) may mediate Rho-kinase (ROCK-2) up-regulation in coronary endothelial cells. Endocr. Regul., 2013, 47(2), 75-84.
146. Hiroki, J.; Shimokawa, H.; Mukai, Y.; Ichiki, T.; Takeshita, A. Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2005, 326(1), 154-159.
147. Lappano, R.; De Marco, P.; De Francesco, E. M.; Chimento, A.; Pezzi, V.; Maggiolini, M. Cross-talk between GPER and growth factor signaling. J. Steroid Biochem. Mol. Biol., 2013, 137, 50-56.
148. Palmieri, D.; Perego, P.; Palombo, D. Apigenin inhibits the TNFalpha- induced expression of eNOS and MMP-9 via modulating Akt signalling through oestrogen receptor engagement. Mol. Cell. Biochem., 2012, 371(1-2), 129-136.
149. Wingrove, C. S.; Garr, E.; Godsland, I. F.; Stevenson, J. C. 17betaoestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim. Biophys. Acta, 1998, 1406(2), 169-174.
150. Deschamps, A. M.; Murphy, E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am. J. Physiol. Heart Circ. Physiol., 2009, 297(5), H1806-H1813.
151. Gruchow, H. W.; Anderson, A. J.; Barboriak, J. J.; Sobocinski, K. A. Postmenopausal use of estrogen and occlusion of coronary arteries. Am. Heart J., 1988, 115(5), 954-963.
152. Matthews, K. A.; Meilahn, E.; Kuller, L. H.; Kelsey, S. F.; Caggiula, A. W.; Wing, R. R. Menopause and risk factors for coronary heart disease. N. Engl. J. Med., 1989, 321(10), 641-646.
153. Pines, A.; Mijatovic, V.; van der Mooren, M. J.; Kenemans, P. Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur. J. Obstet. Gynecol. Reprod. Biol., 1997, 71(2), 193-197.
154. Cherry, N.; Gilmour, K.; Hannaford, P.; Heagerty, A.; Khan, M. A.; Kitchener, H.; McNamee, R.; Elstein, M.; Kay, C.; Seif, M.; Buckley, H. Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet, 2002, 360(9350), 2001-2008.
155. Clarke, S. C.; Kelleher, J.; Lloyd-Jones, H.; Slack, M.; Schofiel, P. M. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT atherosclerosis study. BJOG, 2002, 109(9), 1056-1062.
156. Manson, J. E.; Hsia, J.; Johnson, K. C.; Rossouw, J. E.; Assaf, A. R.; Lasser, N. L.; Trevisan, M.; Black, H. R.; Heckbert, S. R.; Detrano, R.; Strickland, O. L.; Wong, N. D.; Crouse, J. R.; Stein, E.; Cushman, M. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med., 2003, 349(6), 523-534.
157. Khalil, R. A. Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease. Cardiovasc. Hematol. Agents Med. Chem., 2010, 8(1), 29- 46.
158. Gorgoulis, V. G.; Pratsinis, H.; Zacharatos, P.; Demoliou, C.; Sigala, F.; Asimacopoulos, P. J.; Papavassiliou, A. G.; Kletsas, D. p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab. Invest., 2005, 85(4), 502- 511.
159. Sophonsritsuk, A.; Appt, S. E.; Clarkson, T. B.; Shively, C. A.; Espeland, M. A.; Register, T. C. Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause. Menopause, 2013, 20(5), 540-547.
160. Novensa, L.; Novella, S.; Medina, P.; Segarra, G.; Castillo, N.; Heras, M.; Hermenegildo, C.; Dantas, A. P. Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERalpha/ERbeta balance in female mice. PLoS One, 2011, 6(9), e25335.
161. Arefin, S.; Simoncini, T.; Wieland, R.; Hammarqvist, F.; Spina, S.; Goglia, L.; Kublickiene, K. Vasodilatory effects of the selective GPER agonist G-1 is maximal in arteries of postmenopausal women. Maturitas, 2014, 78(2), 123-130.
162. White, R. E.; Han, G.; Dimitropoulou, C.; Zhu, S.; Miyake, K.; Fulton, D.; Dave, S.; Barman, S. A. Estrogen-induced contraction of coronary arteries is mediated by superoxide generated in vascular smooth muscle. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(4), H1468-H1475.
163. Wang, M.; Jiang, L.; Monticone, R. E.; Lakatta, E. G. Proinflammation: The key to arterial aging. Trends Endocrinol. Metab., 2014, 25(2), 72-79.
164. Grandas, O. H.; Mountain, D. H.; Kirkpatrick, S. S.; Cassada, D. C.; Stevens, S. L.; Freeman, M. B.; Goldman, M. H. Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure. J. Vasc. Surg., 2009, 49(1), 185-191.
165. Lewandowski, K. C.; Komorowski, J.; Mikhalidis, D. P.; Bienkiewicz, M.; Tan, B. K.; O'Callaghan, C. J.; Lewinski, A.; Prelevic, G.; Randeva, H. S. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J. Clin. Endocrinol. Metab., 2006, 91(8), 3123-3130.
166. Zanger, D.; Yang, B. K.; Ardans, J.; Waclawiw, M. A.; Csako, G.; Wahl, L. M.; Cannon, R. O. 3rd, Divergent effects of hormone ther apy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J. Am. Coll. Cardiol., 2000, 36(6), 1797-1802.
167. Cid, M. C.; Kleinman, H. K.; Grant, D. S.; Schnaper, H. W.; Fauci, A. S.; Hoffman, G. S. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J. Clin. Invest., 1994, 93(1), 17-25.
168. Harman, S. M.; Black, D. M.; Naftolin, F.; Brinton, E. A.; Budoff, M. J.; Cedars, M. I.; Hopkins, P. N.; Lobo, R. A.; Manson, J. E.; Merriam, G. R.; Miller, V. M.; Neal-Perry, G.; Santoro, N.; Taylor, H. S.; Vittinghoff, E.; Yan, M.; Hodis, H. N. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann. Intern. Med., 2014, 161(4), 249- 260.
169. Pradhan, A. D.; Manson, J. E.; Rossouw, J. E.; Siscovick, D. S.; Mouton, C. P.; Rifai, N.; Wallace, R. B.; Jackson, R. D.; Pettinger, M. B.; Ridker, P. M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study. JAMA, 2002, 288(8), 980-987.
170. Cushman, M.; Meilahn, E. N.; Psaty, B. M.; Kuller, L. H.; Dobs, A. S.; Tracy, R. P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler. Thromb. Vasc. Biol., 1999, 19(4), 893-899.
171. Tanaka, N.; Yonekura, H.; Yamagishi, S.; Fujimori, H.; Yamamoto, Y.; Yamamoto, H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem., 2000, 275(33), 25781-257890.
172. Morris-Rosenfeld, S.; Blessing, E.; Preusch, M. R.; Albrecht, C.; Bierhaus, A.; Andrassy, M.; Nawroth, P. P.; Rosenfeld, M. E.; Katus, H. A.; Bea, F. Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression. Eur. J. Clin. Invest., 2011, 41(11), 1164-1171.